Nimotop S (Nimodipine)

• Nimodipine acts on the cerebrovascular system to manage conditions associated with vessel constriction.
• Prevention of cerebral vasospasm after subarachnoid hemorrhage: reduces the incidence of delayed ischemic neurological deficits.
• Adjunct in acute cerebral vasospasm management: supports restoration of cerebral blood flow.

• Nimodipine selectively blocks L‑type calcium channels in vascular smooth muscle, with a higher affinity for cerebral arteries. This antagonism reduces calcium influx, leading to preferential dilation of cerebral vessels, which mitigates vasospasm and improves cerebral perfusion after subarachnoid hemorrhage.

Nimodipine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Hypotension: mild to moderate drop in blood pressure.
• Headache: transient cranial discomfort.
• Nausea: occasional gastrointestinal upset.
• Flushing: warmth and redness of the skin.
• Dizziness: sensation of light‑headedness.
• Tachycardia: increased heart rate.

Serious or Rare Side Effects

• Severe hypotension: marked blood pressure reduction requiring intervention.
• Myocardial infarction: rare cardiac ischemic events.
• Allergic reaction: rash, itching, or anaphylaxis.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Thrombocytopenia: low platelet count.
• Seizures: infrequent neurologic events.

• Before initiating therapy, clinicians should consider several safety measures.
• Monitor blood pressure: watch for excessive hypotension during infusion.
• Avoid rapid infusion: administer over the recommended time to reduce cardiovascular stress.
• Use with caution in hepatic impairment: adjust dosing if liver function is compromised.
• Assess for drug interactions: review concomitant medications that affect vascular tone.
• Do not use in patients with known hypersensitivity to nimodipine or related compounds.
• Store at ambient temperature: keep in original packaging, protect from moisture and light.

Nimodipine can interact with other drugs, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Concurrent use with other potent vasodilators: may cause severe hypotension.
• Combination with beta‑blockers: risk of additive blood pressure lowering.
• Co‑administration with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increases plasma concentrations.

Moderate Interactions (Monitor Closely)

• Use with other calcium channel blockers: may enhance vasodilatory effects.
• Concomitant diuretics: can affect electrolyte balance and blood pressure.
• Interaction with antiplatelet agents: may increase bleeding tendency.